Bovine Ultra-Long CDR3 Picobodies
Explore the forefront of antibody research with monoclonal Bovine ultra-long CDR3 picobodies. Aligned with our commitment to scientific advancement, we introduce an opportunity to investigate Bovine Picobodies, incorporating "Single Bcell Sorting" and Directed Sequencing of ultralong-CDR3s.
What sets Bovine Picobodies apart?
These binding domains, sourced exclusively from Bovines, exhibit compactness and stability. With a small size ranging from 3 to 5 kiloDaltons (kDa), they mark an advancement in antibody technology. Derived from a specialized subset of Bovine ultralong-CDR3-containing antibodies, Picobodies ...Read more
Bovine Ultra-Long CDR3 Picobodies
Explore the forefront of antibody research with monoclonal Bovine ultra-long CDR3 picobodies. Aligned with our commitment to scientific advancement, we introduce an opportunity to investigate Bovine Picobodies, incorporating "Single Bcell Sorting" and Directed Sequencing of ultralong-CDR3s.
What sets Bovine Picobodies apart?
These binding domains, sourced exclusively from Bovines, exhibit compactness and stability. With a small size ranging from 3 to 5 kiloDaltons (kDa), they mark an advancement in antibody technology. Derived from a specialized subset of Bovine ultralong-CDR3-containing antibodies, Picobodies offer potential for targeted therapy development.
Numerous possibilities
While in the nascent stages of preclinical development, picobody-derived recombinant antibodies, can be formatted into "knobbodies" and bispecific antibodies,and exhibit novel efficacy in binding viral and cancer target epitopes. This heralds a new era of precision medicine, where previously inaccessible targets become attainable.
Join us at the forefront of antibody innovation with LAMPIRE's Bovine Bcell technology. Explore the potential of Picobodies.
Read less